Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Relief as Measles and polio vaccines arriveon July 21, 2019 at 2:00 pm
This is after the arrival of a consignment of 2.2 million doses of polio vaccine and 1.9 million doses of Measles Rubella (MR ... SEE ALSO :Measles kills more than Ebola Ms Kariuki said the vaccines ... […]
- The vaccine challenge isn’t just about getting shotson July 19, 2019 at 5:05 pm
EBOLA, MEASLES and polio can all be prevented with vaccines that provide high degrees of immunity. Yet outbreaks of all three rumble on in different places, causing illness and death. While the ... […]
- The Ebola outbreak in Congo is now considered an international health emergency, according to the World Health Organizationon July 19, 2019 at 4:05 pm
newborn babies An Ebola case has been discovered in a city of 1.2 million people — a 'game changer' that makes fighting the outbreak much more difficult 9 dangerous diseases that could be prevented by ... […]
- How Congo's Ebola outbreak turned into a global emergency: A timeline of key eventson July 18, 2019 at 2:28 pm
Nov. 5 — Uganda starts administering the Ebola vaccine to some health workers in case the outbreak ... Feb. 27 — A second Ebola treatment center is set on fire in Butembo. March 9 — Militant group ... […]
- Congo soldiers, police to enforce Ebola emergency measureson July 18, 2019 at 8:14 am
Health workers have faced misinformation and even deadly attacks that have hampered the critical work of tracing contacts of infected people and deploying an experimental but effective Ebola vaccine. ... […]
- TIMELINE-How a Congo Ebola outbreak became a global concernon July 18, 2019 at 5:06 am
The announcement comes eight days after another Ebola outbreak in western Congo was successfully contained with the use of an experimental new vaccine from Merck. WHO head Tedros Adhanom Ghebreyesus ... […]
- WHO declares a public health emergency over Congo’s Ebola outbreakon July 17, 2019 at 1:53 pm
Science News. Vol. 195, March 16, 2019, p. 9. H. Thompson. Ebola vaccinations begin in Congo. Science News Online, May 21, 2018. H. Thompson. What we know about the Ebola outbreak, and the vaccine ... […]
- Why the Latest Ebola Outbreak Raises Fears Across Borderson July 17, 2019 at 12:28 pm
The WHO has backed the introduction of a second vaccine, with Johnson & Johnson’s experimental treatment the most likely candidate. 5. How far could Ebola spread? The WHO had previously stopped short ... […]
- AP Explains: Why Ebola is now an international emergencyon July 17, 2019 at 11:47 am
An experimental Ebola vaccine has been effective in its first widespread use, and more than 163,000 people have been vaccinated. The vaccine's testing was sped up during the West African Ebola ... […]
- Ebola Outbreak in Congo Declared a Global Health Emergencyon July 17, 2019 at 10:56 am
The outbreak, which began in August 2018, has infected more than 2,300 people and killed more than 1,500, according to a July 9 WHO ... Why Latest Ebola Outbreak Raises Fears Across Borders: QuickTake ... […]
via Bing News